AKAP4 and ductal breast carcinoma in situ: As shown in Figure 7A, 100% DCIS (4/4), 77% IDC (64/83) and 100% ILC (4/4) patients showed humoral response against AKAP4 with mean antibody titers of 0.61±0.08, 0.73±0.04 and 0.51±0.07 respectively (Figure S1B).